Financial Architects (New Jersey)’s Supernus Pharmaceuticals SUPN Stock Holding History

Financial Architects (New Jersey)’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-200	Closed	-$7K	–	1522
2018 Q4	$7K	Buy	+200	New	+$8.6K	﹤0.01%	1081
2018 Q2	–	Sell	-621	Closed	-$28K	–	1495
2018 Q1	$28K	Sell	621 -113	-15%	-$4.72K	0.01%	804
2017 Q4	$30K	Buy	734 +120	+20%	+$4.74K	0.01%	851
2017 Q3	$25K	Sell	614 -239	-28%	-$10.3K	﹤0.01%	912
2017 Q2	$37K	Buy	853 +71	+9%	+$2.53K	0.01%	780
2017 Q1	$24K	Hold	782	–	–	﹤0.01%	888
2016 Q4	$20K	Sell	782 -302	-28%	-$6.75K	﹤0.01%	841
2016 Q3	$27K	Buy	1,084 +978	+923%	+$22.1K	0.01%	761
2016 Q2	$2K	Hold	106	–	–	﹤0.01%	1335
2016 Q1	$2K	Buy	+106	New	+$1.38K	﹤0.01%	1072
2015 Q3	–	Sell	-2,106	Closed	-$36K	–	818
2015 Q2	$36K	Buy	+2,106	New	+$30K	0.01%	506

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Financial Architects (New Jersey)'s SUPN Position: Q1 2019 in Review

Financial Architects (New Jersey) sold out of Supernus Pharmaceuticals (SUPN) in Q1 2019, closing a stake of 200 shares — an estimated $7K sold.

Financial Architects (New Jersey) first reported a position in SUPN in Q2 2015 and held it in 11 quarters. The position peaked at $37K in Q2 2017. 289 funds tracked by Wall St. Rank hold SUPN as of Q1 2019.

Financial Architects (New Jersey) reported no remaining Supernus Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Financial Architects (New Jersey) sold 200 Supernus Pharmaceuticals shares in Q1 2019, an estimated $7K.
Financial Architects (New Jersey) first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 11 quarters.
Financial Architects (New Jersey)'s Supernus Pharmaceuticals position peaked at $37K in Q2 2017.
289 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q1 2019, filed 3 May 2019.